Finoriq research workspace
Apollomics Inc. (APLM) Historical Metrics
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery. Review APLM fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
- Company
- Apollomics Inc. (APLM)
- Ticker
- APLM
- Market Cap
- $40.7M
- Latest Price
- $18.56
- Industry
- Biotech & Pharma
Apollomics Inc. (APLM) Current Valuation Metrics
Static valuation preview for Apollomics Inc. (APLM). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -130.9% | Net Income | TTM FY 2024 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -69.9% | Operating Cash Flow | TTM FY 2024 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.